AtriCure (ATRC) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and AtriCure published the results on November 3, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. AtriCure reports EPS two ways: GAAP, under the accounting rules every US filer follows, and adjusted, per diluted share, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• AtriCure's release headlines adjusted EPS of $0.18, which is per basic share. Per diluted share, the figure shown here, it was $0.17. The only adjustment in the quarter was a $4.5 million acquired in-process research and development payment.

Source: AtriCure Q3 2026 results release, November 3, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How AtriCure splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• AtriCure's United States revenue was $128 million in Q3 2026, up 17% from $109 million in Q3 2025, 83% of total revenue.
• AtriCure's International revenue was $26.4 million in Q3 2026, up 6% from $25.0 million in Q3 2025, 17% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q3 2026 release, AtriCure said:

“Full year 2026 revenue is now projected to be approximately $606 million to $610 million, and management also projects full year 2026 adjusted EBITDA of approximately $91 million to $94 million.”

“Full year 2026 net income per share is expected to be in the range of $0.21 to $0.27 and adjusted earnings per share of approximately $0.40 to $0.46.”

Source: AtriCure Q3 2026 release, Nov 3, 2026.

This is the company's own guidance as of Nov 3, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the ATRC forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP revenue and diluted EPS, each as first reported in that quarter's release or 10-Q.

We do not hold a confirmed date for AtriCure's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 3, 2026

AtriCure's Q3 2026 revenue was $154.5 million, up 15.0% (15.1% in constant currency). The United States was $128.0 million, up 17.1%, and international revenue was $26.4 million, up 5.8%. AtriCure sells to medical centers through a direct sales force in the United States, Germany, France, the United Kingdom, the Benelux region, Australia and Canada, and through distributors elsewhere. (AtriCure Q3 2026 release (8-K Exhibit 99.1), Nov 3, 2026; AtriCure Form 10-K, 2025, Feb 19, 2026)

AtriCure reports four product franchises. In the United States, appendage management (the AtriClip devices) was the largest at $51.6 million, up 13.5%, followed by open ablation at $43.0 million, up 20.8%, pain management at $28.1 million, up 34.6%, and minimally invasive ablation at $5.4 million, down 27.5%. (AtriCure Form 10-Q, Q3 2026, Nov 4, 2026; AtriCure Q3 2026 release (8-K Exhibit 99.1), Nov 3, 2026)

AtriCure credited U.S. growth to the cryoSPHERE MAX probe for post-operative pain management, the EnCompass clamp in open ablation, and the AtriClip FLEX-Mini and AtriClip PRO-Mini devices. It said minimally invasive ablation fell because Hybrid procedures continued to decline as physicians adopt PFA catheters. (AtriCure Q3 2026 release (8-K Exhibit 99.1), Nov 3, 2026; AtriCure Form 10-Q, Q3 2026, Nov 4, 2026)

AtriCure's products are used mostly during open-heart surgery for another condition, such as a valve repair or coronary artery bypass, where ablation or appendage exclusion is done alongside the main procedure. Its cryoICE cryoSPHERE and cryoXT probes freeze nerves to give temporary relief of post-operative pain. (AtriCure Form 10-K, 2025, Feb 19, 2026)

AtriCure earned $0.08 per diluted share in Q3 2026, against a loss of $0.01 a year earlier, on net income of $4.1 million. Gross margin rose 180 basis points to 77.3%, which AtriCure attributed to favorable product and geographic mix, and income from operations was $4.4 million against $0.2 million. (AtriCure Q3 2026 release (8-K Exhibit 99.1), Nov 3, 2026)

AtriCure's adjusted EPS adds back acquired in-process research and development, contingent consideration changes, legal settlements, intangible impairments and debt extinguishment. In Q3 2026 the only item was a $4.5 million IPR&D milestone payment, which lifted adjusted EPS to $0.17 per diluted share ($0.18 per basic share). Research and development expense rose 40.3%, driven by that payment, $3.0 million of higher clinical costs mostly for BoxX-NoAF enrollment and $1.6 million of new product development. (AtriCure Q3 2026 release (8-K Exhibit 99.1), Nov 3, 2026; AtriCure Form 10-Q, Q3 2026, Nov 4, 2026)

AtriCure's diluted share count was 49,831 thousand against 47,920 thousand. Its effective tax rate was negative 1.2% in the quarter, which the 10-Q attributes to valuation allowances; AtriCure uses the discrete method for its quarterly tax provision. (AtriCure Q3 2026 release (8-K Exhibit 99.1), Nov 3, 2026; AtriCure Form 10-Q, Q3 2026, Nov 4, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

AtriCure gives full-year guidance in its release. It now projects 2026 revenue of about $606 million to $610 million, adjusted EBITDA of about $91 million to $94 million, GAAP net income per share of $0.21 to $0.27 and adjusted EPS of about $0.40 to $0.46. Through nine months, revenue was $449.3 million and adjusted EBITDA $71.2 million. (AtriCure Q3 2026 release (8-K Exhibit 99.1), Nov 3, 2026)

A consensus figure is the average of the models published by the analysts who cover AtriCure, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones AtriCure's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning ATRC is on is ATRC a buy or a sell?, what analysts expect next is on the ATRC forecast, and what the company does is on the AtriCure (ATRC) stock page.

Every number on this page can be traced to a document AtriCure published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.